polarityTE
-
PolarityTE Secures $22.5 Million Financing to Advance SkinTE Phase III Pivotal Study in Diabetic Foot Ulcers
PolarityTE Secures $22.5 Million Financing to Advance SkinTE Phase III Pivotal Study in Diabetic Foot Ulcers
-
PolarityTE Reports Third Quarter 2022 Financial Results and Provides Business Update
PolarityTE provided a business update and reported financial results for the quarterly period ended September 30, 2022.
-
PolarityTE Confirms Receipt of Unsolicited, Non-Binding Offer to Acquire the Company
PolarityTE confirmed that on November 1, 2022, it received an unsolicited, non-binding offer (followed by an amended offer…
-
Excess Equipment Sale for BioUtah Members
Excess Equipment Sale for BioUtah Members
-
PolarityTE Reports Second Quarter 2022 Financial Results and Provides Business Update
PolarityTE provided a business update and reported financial results for the quarterly period ended June 30, 2022.
-
PolarityTE Announces $8.0 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
PolarityTE announced that it has entered into securities purchase agreements with a single healthcare-focused institutional investor
-
PolarityTE to Effectuate 1-for-25 Reverse Stock Split
PolarityTE announced that the Company will effectuate a 1-for-25 reverse stock split of the Company’s issued and outstanding…
-
PolarityTE Reports First Quarter 2022 Financial Results and Provides Business Update
PolarityTE provided a business update and reported financial results for the three-month period ended March 31, 2022.
-
PolarityTE Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE®
PolarityTE announced that the U.S. FDA granted a Regenerative Medicine Advanced Therapy (RMAT) designation to SkinTE under the…
-
PolarityTE Announces First Subject Enrolled in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers
SALT LAKE CITY, May 3, 2022 /PRNewswire/ — PolarityTE, Inc. (Nasdaq: PTE) today announced the enrollment of the…
-
PolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business Update
SALT LAKE CITY, March 30, 2022 /PRNewswire/ — PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue…
-
PolarityTE Announces $5.0 Million Registered Direct Offering
PolarityTE Announces $5.0 Million Registered Direct Offering
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
